Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) attributable profit jumped 21% to 4.55 billion yuan in 2024 from 3.77 billion yuan in 2023, according to a Thursday filing with the Hong Kong bourse.
The Chinese pharmaceutical company's earnings per share rose to 1.23 yuan from 1.02 yuan a year earlier.
Operating income edged up 5.75% to 275.3 billion yuan from 260.3 billion yuan a year prior.